Clinical trial
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study
NCT02106364 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- February 28, 2015
- Completion date
- June 30, 2016
- Enrollment
- 0 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.